Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Velazquez

Showing results (81-90 of 357) with videos related to

Pageof 36
Sort By:
American Heart Journal|May 17, 2011
Chronic noncommunicable cardiovascular and pulmonary disease in sub-Saharan Africa: an academic model for countering the epidemicGerald S Bloomfield, Sylvester Kimaiyo, E Jane Carter, et al.
European Heart Journal|May 17, 2019
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trialDavid A Morrow, Eric J Velazquez, Adam D DeVore, et al.
American Journal of Hypertension|September 15, 2004
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertensionKenneth A Jamerson, George L Bakris, Chuan-Chuan Wun, et al.
European Journal of Heart Failure|December 22, 2019
Association between systolic ejection time and outcomes in heart failure by ejection fractionPriyesh A Patel, Andrew P Ambrosy, Matthew Phelan, et al.
Journal of the American College of Cardiology|August 29, 2020
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System AntagonistsAndrew P Ambrosy, Eugene Braunwald, David A Morrow, et al.
Circulation. Heart Failure|July 18, 2013
Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF studyMichael M Givertz, Douglas L Mann, Kerry L Lee, et al.
Annals of Vascular Surgery|October 6, 2023
The Impact of Ejection Fraction on Major Adverse Limb Events after Lower Extremity RevascularizationYasser Jamil, Joshua Huttler, Dana Alameddine, et al.
JAMA Cardiology|December 12, 2019
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF TrialAdam D DeVore, Eugene Braunwald, David A Morrow, et al.
The New England Journal of Medicine|December 5, 2008
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsKenneth Jamerson, Michael A Weber, George L Bakris, et al.
The American Journal of Cardiology|September 11, 2007
Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of <or=35%Kevin L Thomas, Sana M Al-Khatib, Richard C Kelsey, et al.
Pageof 36

Showing results (81-90 of 357) with videos related to

Sort By:
Pageof 36
American Heart Journal|May 17, 2011
Chronic noncommunicable cardiovascular and pulmonary disease in sub-Saharan Africa: an academic model for countering the epidemicGerald S Bloomfield, Sylvester Kimaiyo, E Jane Carter, et al.
European Heart Journal|May 17, 2019
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trialDavid A Morrow, Eric J Velazquez, Adam D DeVore, et al.
American Journal of Hypertension|September 15, 2004
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertensionKenneth A Jamerson, George L Bakris, Chuan-Chuan Wun, et al.
European Journal of Heart Failure|December 22, 2019
Association between systolic ejection time and outcomes in heart failure by ejection fractionPriyesh A Patel, Andrew P Ambrosy, Matthew Phelan, et al.
Journal of the American College of Cardiology|August 29, 2020
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System AntagonistsAndrew P Ambrosy, Eugene Braunwald, David A Morrow, et al.
Circulation. Heart Failure|July 18, 2013
Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF studyMichael M Givertz, Douglas L Mann, Kerry L Lee, et al.
Annals of Vascular Surgery|October 6, 2023
The Impact of Ejection Fraction on Major Adverse Limb Events after Lower Extremity RevascularizationYasser Jamil, Joshua Huttler, Dana Alameddine, et al.
JAMA Cardiology|December 12, 2019
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF TrialAdam D DeVore, Eugene Braunwald, David A Morrow, et al.
The New England Journal of Medicine|December 5, 2008
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsKenneth Jamerson, Michael A Weber, George L Bakris, et al.
The American Journal of Cardiology|September 11, 2007
Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of <or=35%Kevin L Thomas, Sana M Al-Khatib, Richard C Kelsey, et al.
Pageof 36